Antiplatelet drug effective despite genetic profile

Antiplatelet therapy with the new drug ticagrelor is effective regardless of genetic traits that can cause poor response to existing treatment, research suggests.

Antiplatelet drug could result in patients receiving faster access to treatment (Photograph: SPL)
Antiplatelet drug could result in patients receiving faster access to treatment (Photograph: SPL)

A sub-study of the PLATO trial showed that ticagrelor, which is currently under development, was effective at reducing acute coronary syndromes (ACS) in patients with genetic polymorphisms which cause a poor response to conventional drugs.

The study, published in The Lancet, suggests treatment with ticagrelor would mean more patients could receive access to effective treatment.

At present, ACS is treated using dual antiplatelet therapy in the form of aspirin plus clopidogrel or prasugrel.

However, about 10-15% of patients have genetic variations in the genes CYP2C19 and ABCB1, which can cause patients to suffer a poor response to clopidogrel.

A blood test to screen for the genetic polymorphisms would identify those who may respond poorly to treatment, but is often unavailable in UK primary care.

Researchers used data from 10,285 patients who were part of the PLATO trial and agreed to genetic testing.

The primary outcome was a composite of cardiovascular death, MI, or stroke, with 12 months follow-up.

Among patients with the any loss-of-function genotype, ACS occurred less often with ticagrelor than clopidogrel.

However, in patients without a loss-of-function allele there was no difference in efficacy between the two drugs.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

GP time per patient slumps to lowest level in half a decade

GP time per patient slumps to lowest level in half a decade

GP time available per patient has dropped by six and a half minutes since 2015 -...

An uncompromising defender of the NHS: colleagues remember Dr Ron Singer

An uncompromising defender of the NHS: colleagues remember Dr Ron Singer

Colleagues and friends have paid tribute after the death of East London GP Dr Ron...

COVID-19 death rate highest among BAME groups, delayed PHE review confirms

COVID-19 death rate highest among BAME groups, delayed PHE review confirms

Death rates from COVID-19 are highest among patients from BAME groups, according...

GPs face hundreds of complaints over shielding and PPE during pandemic

GPs face hundreds of complaints over shielding and PPE during pandemic

GP practices have faced hundreds of complaints over issues including shielding and...

More than 3,600 GP partners lost in four years as decline accelerates

More than 3,600 GP partners lost in four years as decline accelerates

The number of full-time equivalent (FTE) GP partners in England fell by 3,636 between...

COVID-19 pandemic leaves 2.4m patients stuck in cancer care backlog

COVID-19 pandemic leaves 2.4m patients stuck in cancer care backlog

Around 2.4m patients are waiting longer for cancer tests or treatment because of...